<CTIC>
>>I figure with an approved drug with about $30m sales, a shot at $100m+ sales if they get a label expansion>>
Considering the level of activity in the clinics, that might not be impossible.
Clinical Trials
Forty-two TRISENOX® clinical trials studying the drug alone and in combination with other therapies are ongoing, are planned to begin in the near future, or were recently completed. Twelve of these 42 trials are being done under the sponsorship of the National Cancer Institute (NCI) in the United States, under a Cooperative Research and Development Agreement (CRADA) with us. Preliminary data from ongoing clinical trials have shown encouraging responses in patients with multiple myeloma, MDS, CML, lymphoma, prostate cancer, and neuroblastoma.
Ten of these studies are being conducted in patients with various solid tumors for which preclinical studies have shown potential activity of TRISENOX®. In addition to the 42 current trials, 4 trials in various solid tumors have been approved in concept by the NCI for inclusion in the CRADA program, and 13 trials are planned by independent investigators for the coming year. |
